EFFECTS OF DECREASED CYCLOSPORINE DOSING

减少环孢素剂量的影响

• 批准号: 6263452
• 负责人: JOHN C CURTIS
• 金额: $ 2.95万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6263452
• 关键词: clinical research; combination chemotherapy; cyclosporines; dosage; human subject; human therapy evaluation; immunosuppression; kidney disorder chemotherapy; kidney transplantation; mycophenolic acid; prednisone

Triple therapy with cyclosporine, CellCept (Mofetil), and prednisone is becoming the standard chronic maintenance regimen in the USA for renal transplant patients. CellCept has replaced azathioprine and appears to be a more potent immunosuppressive drug. Yet the addition of greater immunosuppression has not yet been shown to result in the ability to reduce the doses of the other immunosuppressive agents. Previous experience with decreasing cyclosporine for financial reasons has demonstrated that the majority of patients could reduce their dose of cyclosporine without provoking acute rejection. We believe that this may also result in higher GFR, lower serum creatinine, lower blood pressure and improved plasma lipids. Also, decreasing the amount of cyclosporine would result in decreased costs. Depending on the results of this pilot study, we will resubmit a proposal to the company to increase the number of patients in order to increase the statistical power.

环孢素、CellCept （Mofetil）和强的松的三联治疗正在成为美国肾移植患者的标准慢性维持方案。CellCept已经取代了硫唑嘌呤，似乎是一种更有效的免疫抑制药物。然而，增加更大的免疫抑制尚未显示导致减少其他免疫抑制剂剂量的能力。以往因经济原因减少环孢素的经验表明，大多数患者可以减少环孢素的剂量，而不会引起急性排斥反应。我们认为这也可能导致GFR升高、血清肌酐降低、血压降低和血脂改善。此外，减少环孢素的用量也会降低成本。根据本次试点研究的结果，我们将重新向公司提交增加患者数量的提案，以提高统计效力。